Matvey Lukashev

Matvey Lukashev Email and Phone Number

Drug development consultant (pro bono) @ ALS Therapy Development Institute
Boston, MA, US
Matvey Lukashev's Location
Cambridge, Massachusetts, United States, United States
Matvey Lukashev's Contact Details

Matvey Lukashev personal email

n/a
About Matvey Lukashev

• 25 years of industry experience across all stages of drug development in oncology, immunology/fibrosis, and neurology • Broad therapeutic indication and target class experience in translational research, clinical dvelopment, and discovery settings• Record of successful project initiation and cross-functional project team leadership in translational and discovery research• Familiarity with clinical development, clinical trial operations and logistics for biomarker studies

Matvey Lukashev's Current Company Details
ALS Therapy Development Institute

Als Therapy Development Institute

View
Drug development consultant (pro bono)
Boston, MA, US
Website:
als.net
Employees:
61
Matvey Lukashev Work Experience Details
  • Als Therapy Development Institute
    Drug Development Consultant (Pro Bono)
    Als Therapy Development Institute
    Boston, Ma, Us
  • Nervgen Pharma Corp.
    Vice President, Research And Preclinical Development
    Nervgen Pharma Corp. Sep 2022 - Present
    Vancouver, British Columbia, Ca
    Discovery and preclinical development of therapeutics targeting CNS repair
  • Als Therapy Development Institute
    Drug Development Consultant (Pro Bono)
    Als Therapy Development Institute Sep 2022 - Present
    Watertown, Massachusetts, Us
  • Als Therapy Development Institute
    Vice President, Translational Sciences
    Als Therapy Development Institute Jan 2021 - Sep 2022
    Watertown, Massachusetts, Us
  • Als Therapy Development Institute
    Senior Director, Cell Biology And Translational Research
    Als Therapy Development Institute Jan 2018 - Jan 2021
    Watertown, Massachusetts, Us
    Built and led a new translational research function encompassing patient genomics and phenomics, stem cell biology (iPSC and their derivatives) and genome editing for biomarker, target and drug discovery in amyotrophic lateral sclerosis.
  • Als Therapy Development Institute
    Director, Cell Biology And Translational Research
    Als Therapy Development Institute Aug 2013 - Dec 2017
    Watertown, Massachusetts, Us
  • Cellibrium Biosciences
    Sab Member
    Cellibrium Biosciences Sep 2021 - Present
  • Biogen Idec
    Principal Scientist
    Biogen Idec Jan 2007 - Aug 2012
    Cambridge, Ma, Us
    • Tecfidera® Research Lead (through 2010), Program Team member. Characterized the molecular and cellular mechanisms of action, led biomarker discovery supporting clinical development of Tecfidera®. Provided and led research support for multiple aspects of the clinical development program, including the publication regulatory, legal, and risk mitigation strategies. Participated in foreign regulatory agency discussions and meetings. Designed biomarker strategies for Phase 2 and 3 clinical studies. • Project leader for an exploratory monoclonal antibody target validation program in immunology. Identified the target through analysis of clinical genomic data. Developed the project, led cross-functional project team.• Project leader for small molecule discovery projects targeting metabolic stress response. Identified the target pathway and molecular intervention points, developed and led the discovery projects focusing on structure-based drug design, biochemical screening, and phenotypic screening approaches.• Recipient of Biogen Idec Outstanding Achievement Award (2012)
  • Biogen Idec
    Senior Scientist
    Biogen Idec 2003 - 2006
    Cambridge, Ma, Us
    • BG12 (Tecfidera®) Research Lead (since 2005). Led BG12 mechanism of action analysis and biomarker discovery. Developed MOA-based rationale for potential new indications, combination therapy uses, and follow-on compound identification. Supported program-related external opportunity evaluation and due diligence efforts, co-managed external collaborator network.• Using gene expression analysis methods, characterized mechanism of in vivo action, identified candidate biomarkers of drug response and efficacy, and provided data informing therapeutic candidate selection for a pre-IND program developing a monoclonal antibody for treatment of fibrotic disease. Generated data provided a strategic basis for subsequent clinical development of the therapy.
  • Biogen,
    Scientist Ii
    Biogen, Oct 1998 - Dec 2002
    • Co-leader of the Angiogenesis program. Responsible for selection and validation of targets and candidate therapeutic agents for modulation of angiogenesis. • Led mechanism of action studies and identification of clinically relevant pharmacodynamic biomarkers to inform preclinical and clinical development of a monoclonal antibody for treatment of solid tumors. Established a predictive in vitro cell-based platform for preclinical prediction of tumor response and biomarker discovery. • Co-developed a new approach to the mining of transcript profiling data.• Member, Joint Research Management Committee and Head, genomics data mining team for a tumor antigen discovery program (Biogen-EOS Biotechnology collaboration).
  • Ucsf
    Postgraduate Researcher
    Ucsf 1994 - 1998
    San Francisco, California, Us
  • Ucsf Medical Center
    Postdoc
    Ucsf Medical Center 1991 - 1994
    San Francisco, Ca, Us

Matvey Lukashev Skills

Biomarkers Immunology Drug Discovery Biotechnology Genomics Drug Development Assay Development In Vitro Antibodies Monoclonal Antibodies Biomarker Discovery In Vivo Oncology Clinical Development Inflammation Translational Medicine Signal Transduction Translational Research Cell Cell Culture Molecular And Cellular Biology High Throughput Screening Molecular Biology Biochemistry Validation Cell Signaling Cell Biology Immunoassays Protein Chemistry Biopharmaceuticals Elisa Fibrosis Biologics Western Blotting Flow Cytometry Animal Models Clinical Trials Small Molecules Pharmacology Lifesciences Cancer Drug Design Pharmacodynamics Autoimmune Diseases Protein Purification Ind Purification

Matvey Lukashev Education Details

  • Lomonosov Moscow State University (Msu)
    Lomonosov Moscow State University (Msu)
    Biochemistry. Bioorganic Chemistry
  • Russian Academy Of Medical Sciences
    Russian Academy Of Medical Sciences
    Cell Biology

Frequently Asked Questions about Matvey Lukashev

What company does Matvey Lukashev work for?

Matvey Lukashev works for Als Therapy Development Institute

What is Matvey Lukashev's role at the current company?

Matvey Lukashev's current role is Drug development consultant (pro bono).

What is Matvey Lukashev's email address?

Matvey Lukashev's email address is ml****@****als.net

What is Matvey Lukashev's direct phone number?

Matvey Lukashev's direct phone number is (617) 441*****

What schools did Matvey Lukashev attend?

Matvey Lukashev attended Lomonosov Moscow State University (Msu), Russian Academy Of Medical Sciences.

What are some of Matvey Lukashev's interests?

Matvey Lukashev has interest in Sports, Electronics.

What skills is Matvey Lukashev known for?

Matvey Lukashev has skills like Biomarkers, Immunology, Drug Discovery, Biotechnology, Genomics, Drug Development, Assay Development, In Vitro, Antibodies, Monoclonal Antibodies, Biomarker Discovery, In Vivo.

Who are Matvey Lukashev's colleagues?

Matvey Lukashev's colleagues are David Leblanc, Terri Handler, Alessandro Calo, Thomas Krzystek, Jenny Gore Dwyer, Claire Craven, Glynis Murray.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.